Search | Clinical Trials Finder

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 58
States / cities: Dothan, Alabama • Lancaster, California • Orange, California + 49 more

Conditions: SARS-CoV 2, ARDS
Interventions: Dornase Alfa Inhalation Solution; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Interventions: Social media recruitment, Self-Assessment, Follow-up; Behavioral
Lead sponsor: ZS Associates; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Depression
Interventions: Org 24448, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: High Grade Meningioma
Interventions: Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more

Conditions: Nasal Congestion
Interventions: Sonu Acoustic Resonance Therapy; Device
Lead sponsor: Third Wave Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ulcerative Colitis
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 132
States / cities: Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more

Conditions: Dyspareunia
Interventions: Prasterone; Drug
Lead sponsor: San Diego Sexual Medicine; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Clinically Severe Obesity, Metabolic Complications After Jejunoileal Bypass, Nutritional Complications After Jejunoileal Bypass, Obesity Recidivism, Inadequate Initial Weight Loss, Intestinal Malabsorptive Syndrome, Protein Malnutrition
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Major Depressive Disorder
Interventions: duloxetine hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Essential Tremor
Interventions: Sodium Oxybate, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bingham Farms, Michigan

Conditions: Depressive Disorder, Major
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 28 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions: ABT-888, Cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Davis, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Major Depressive Disorder
Interventions: vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Garden Grove, California • San Diego, California • Torrance, California + 34 more

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Conditions: Severe Hemophilia A
Interventions: Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab, Eloctate ITI; Drug
Lead sponsor: Margaret Ragni; Other
Eligibility: 4 Months to 99 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more

Conditions: Coronary Disease, Diabetes Mellitus
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 15,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more

Conditions: Obesity, Critical Illness
Interventions: Levofloxacin 750 mg IV; Drug
Lead sponsor: Joel Thompson, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

Org 24448 to Treat Major Depression

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Sonu Real-World Use Clinical Study to Treat Moderate to Severe Nasal Congestion

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Phase II ABT-888 With Cyclophosphamide

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Levofloxacin Pharmacokinetics (PK) in the Severely Obese